Sebastian Noe

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications

Quantifying subsurface fracture damage in glaciers using fiber-optic seismology.

Quantifying subsurface fracture damage in glaciers using fiber-optic seismology.

Journal: Science advances
Published: July 23, 2026

Characteristics of late HIV diagnosis in Germany in 2019 and 2020 - A regional analysis.

Characteristics of late HIV diagnosis in Germany in 2019 and 2020 - A regional analysis.

Journal: Infection
Published: July 03, 2026

Quantitative in-vivo full-waveform ultrasound tomography workflow integrating reflection imaging and resolution analysis.

Quantitative in-vivo full-waveform ultrasound tomography workflow integrating reflection imaging and resolution analysis.

Journal: Physics in medicine and biology
Published: June 12, 2026

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Adherence to Hepatocellular Carcinoma Surveillance Guidelines Among People with HIV and Chronic HBV Infection.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: January 14, 2026

Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice.

Persistence on dolutegravir-containing two- and three-drug-regimens in clinical practice.

Journal: International journal of STD & AIDS
Published: October 03, 2025

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.

Journal: AIDS (London, England)
Published: October 02, 2025

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.

Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1.

Journal: AIDS (London, England)
Published: October 02, 2025

Hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus coinfection in Germany.

Hepatitis D virus infection prevalence in persons with human immunodeficiency virus and hepatitis B virus coinfection in Germany.

Journal: Infection
Published: September 14, 2025

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis.

Journal: HIV medicine
Published: June 23, 2025

Trough concentrations of cabotegravir and rilpivirine and their association with detectable viral load in people with HIV on long-acting treatment.

Trough concentrations of cabotegravir and rilpivirine and their association with detectable viral load in people with HIV on long-acting treatment.

Journal: Infection
Published: April 13, 2025

Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.

Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process.

Journal: The lancet. HIV
Published: January 08, 2025

Bayesian Estimation of the Probability of Virologic Failure on Cabotegravir and Rilpivirine Long-Acting in Real Life.

Bayesian Estimation of the Probability of Virologic Failure on Cabotegravir and Rilpivirine Long-Acting in Real Life.

Journal: Cureus
Published: January 02, 2025
Showing 1-12 of 55

Last Updated: 09/26/2026